Octopus AIM VCT PLC : Net Asset Value(s) Octopus AIM VCT

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
27
Octopus AIM VCT PLC : Net Asset Value(s)

Octopus AIM VCT plc

13 July 2018

Net Asset Value

The Board of Octopus AIM VCT plc announces that as at 9 July 2018 the unaudited net asset value of the Ordinary shares was approximately 121.5 pence per share.

The net asset value is stated excluding a final dividend of 3.0 pence per share. The final dividend will be paid on 20 July 2018, to those shareholders on the register on 22 June 2018.

For further information, please contact:

Kate Tidbury                                                                
Octopus Investments Limited                                                    
Tel: 0800 316 2295  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring the $2.7 Billion Bid for Papa John’s: An Investment Insight

Updated Category News Views 229

Papa John’s $2.7 Billion Takeover Bid: Insights into Potential Value Recently, shares of Papa John’s International Inc (NASDAQ:PZZA) experienced a notable surge, leading to a halt in trading due to high volatility. This surprising movement came in light of credible reports suggesting a take-private cash offer of $65 per share from TriArtisan Capital Advisors, totaling...

Continue Reading
Key Highlights from Octopus Apollo VCT plc AGM Results

Updated Category News Views 105

Octopus Apollo VCT plc AGM Results Overview Octopus Apollo VCT plc recently conducted its Annual General Meeting (AGM), showcasing significant engagement from shareholders. The meeting aimed to discuss key resolutions impacting the future direction of the company. Voting Outcomes of the AGM The company disclosed that all resolutions were successfully passed during the...

Continue Reading
Carisma Therapeutics Showcases Strong Financial Performance

Updated Category News Views 104

Carisma Therapeutics Showcases Strong Financial Performance Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, recently released its financial performance for the third quarter of 2024. With a focus on developing innovative immunotherapies, Carisma provided insight into its ongoing projects. Key Developments and Milestones Carisma's...

Continue Reading
Epinephrine Market Growth Insights and Future Potential

Updated Category News Views 112

Overview of the Epinephrine Market The global epinephrine market is on a significant upswing, with recent evaluations estimating its value at USD 3.11 billion and a projected growth to approximately USD 6.39 billion within the next decade. As a critical hormone and neurotransmitter produced by the adrenal glands, epinephrine is essential in treating severe allergic...

Continue Reading
Canadian North Resources Achieves Major Milestones in Q2 2025

Updated Category News Views 183

Canadian North Resources Makes Significant Progress in Operational Strategy Highlights: Canadian North has expanded its bio-metallurgical programs significantly, achieving impressive nickel and cobalt extraction rates through innovative bio-leaching tests. The focus remains on extracting copper and other precious group elements (PGE) metals from the Ferguson Lake Project....

Continue Reading